PNU-120596
(Synonyms: NSC 216666) 目录号 : GC11643
PNU-120596是α7神经元烟碱乙酰胆碱受体(α7nAChR)的正变构调节剂,EC50值为216nM。
Cas No.:501925-31-1
Sample solution is provided at 25 µL, 10mM.
PNU-120596 is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptor (α7nAChR) with an EC50 value of 216nM[1]. α7nAChR is a ligand-gated ion channel. Activation of α7nAChR can affect a series of cellular physiological processes, such as calcium influx, neurotransmitter release, synaptic plasticity and excitatory transmission, and can also induce inflammation, autophagy, necrosis, transcription and apoptosis[2]. PNU-120596 can be used to study neurological diseases[3]. In the presence of PNU-120596 and possibly other positive allosteric modulators, endogenous choline may continuously activate CA1 pyramidal α7nAChR and enhance the excitability of CA1 pyramidal neurons[4].
In vivo, PNU-120596 (3mg/kg) was intraperitoneally injected into 6-OHDA-induced Parkinson's disease (PD) rats for 14 days, which improved motor dysfunction, inhibited neuroinflammation, reduced the expression of JAK2/NF-κB/GSk3β, and promoted the regeneration of dopaminergic neurons in the substantia nigra and striatum[5]. PNU-120596 (1mg/kg) was intravenously injected into rats with myocardial ischemia-reperfusion injury (MIRI), which significantly reduced myocardial infarction area, ultrastructural damage, serum creatine kinase and lactate dehydrogenase, serum proinflammatory cytokine production, myocardial endothelial activation and neutrophil infiltration[6]. PNU-120596 (4mg/kg) was intraperitoneally injected into LPS-induced depression mice, which reduced the expression of 3-hydroxyanthranilic acid dioxygenase (HAAO) in the hippocampus and prefrontal cortex and the formation of microglial quinolinic acid (QUIN)[7].
References:
[1] Uwada J, Nakazawa H, Mikami D, et al. PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptor, directly inhibits p38 MAPK[J]. Biochemical pharmacology, 2020, 182: 114297.
[2] Xu Z Q, Zhang W J, Su D F, et al. Cellular responses and functions of α7 nicotinic acetylcholine receptor activation in the brain: A narrative review[J]. Annals of translational medicine, 2021, 9(6).
[3] Sun F, Jin K, Uteshev V V. A type-II positive allosteric modulator of α7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats[J]. PloS one, 2013, 8(8): e73581.
[4] Kalappa B I, Gusev A G, Uteshev V V. Activation of functional α7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiological levels of choline in the presence of PNU-120596[J]. PloS one, 2010, 5(11): e13964.
[5] Gowayed M A, El-Sayed N S, Matar N A, et al. The α7 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: role of JAK2/NF-κB/GSk3β/TNF-α pathway[J]. Biomedicine & Pharmacotherapy, 2022, 148: 112776.
[6] Li H, Zhang Z Z, Zhan J, et al. Protective Effect of PNU-120596, a Selective Alpha7 Nicotinic Acetylcholine Receptor–positive Allosteric Modulator, on Myocardial Ischemia–reperfusion Injury in Rats[J]. Journal of Cardiovascular Pharmacology, 2012, 59(6): 507-513.
[7] Alzarea S, Abbas M, Ronan P J, et al. The effect of an α-7 nicotinic allosteric modulator PNU120596 and NMDA receptor antagonist memantine on depressive-like behavior induced by LPS in mice: the involvement of brain microglia[J]. Brain Sciences, 2022, 12(11): 1493.
PNU-120596是α7神经元烟碱乙酰胆碱受体(α7nAChR)的正变构调节剂,EC50值为216nM[1]。α7nAChR是一种配体门控离子通道,α7nAChR的激活能够影响一系列细胞生理过程,例如钙内流、神经递质释放、突触可塑性和兴奋性传递等,还能诱导炎症、自噬、坏死、转录和细胞凋亡等[2]。PNU-120596能够用于神经疾病的研究[3]。在PNU-120596和可能的其他阳性变构调节剂存在的情况下,内源性胆碱可能会持续激活含有CA1锥体α7nAChR,增强CA1锥体神经元的兴奋性[4]。
在体内,PNU-120596(3mg/kg)通过腹腔注射治疗6-OHDA诱导的帕金森症(PD)大鼠14天,改善了大鼠的运动功能障碍,抑制了神经炎症,降低了JAK2/NF-κB/GSk3β的表达,促进了黑质和纹状体中多巴胺能神经元的再生[5]。PNU-120596(1mg/kg)通过静脉注射治疗心肌缺血再灌注损伤(MIRI)大鼠,显著降低了心肌梗死面积、超微结构损伤、血清肌酸激酶和乳酸脱氢酶,降低了血清促炎细胞因子产生、心肌内皮活化和中性粒细胞浸润[6]。PNU-120596(4mg/kg)通过腹腔注射治疗LPS诱导的抑郁症小鼠, 降低了海马和前额叶皮层中3-羟基邻氨基苯甲酸双加氧酶(HAAO)的表达和小胶质细胞喹啉酸(QUIN)的形成[7]。
Animal experiment [1]: | |
Animal models | Parkinson’s disease (PD) rats |
Preparation Method | Rats were randomly allocated into six groups: SH: sham rats received saline. Rats administered 6-OHDA were furtherly subdivided into 5 groups: (1) OH: received the vehicle, (2) LD: received oral gavage of levodopa/carbidopa (10/1mg/kg), (3) PNU: received intraperitoneal (i.p) PNU-120596 (3mg/kg), (4) MLA: received i.p. methyllycaconitine citrate (3mg/kg), (5) PNU-120596+MLA: received methyllycaconitine citrate and PNU-120596, i.p. MLA was administered 30 min before PNU-120596. Levodopa/carbidopa and PNU-120596 were dissolved in 5%DMSO/5% Kolliphor HS 15/90% saline. Drugs were administered daily for 14 days; then rats were decapitated, brains excised, left striata were dissected, stored at -80°C, and used for neurochemical analyses. |
Dosage form | 3mg/kg; 14 days; i.p. |
Applications | PNU-120596 improved motor dysfunctions in 6-OHDA induced PD in rats. PNU-120596 halted neuroinflammation manifested as decreased JAK2/NF-κB/GSk3β expression. Nigrostriatal dopaminergic neurons were restored following PNU-120596 treatment. |
References: |
Cas No. | 501925-31-1 | SDF | |
别名 | NSC 216666 | ||
化学名 | 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methyl-1,2-oxazol-3-yl)urea | ||
Canonical SMILES | CC1=CC(=NO1)NC(=O)NC2=CC(=C(C=C2OC)OC)Cl | ||
分子式 | C13H14ClN3O4 | 分子量 | 311.73 |
溶解度 | ≥ 31.2mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.2079 mL | 16.0395 mL | 32.079 mL |
5 mM | 0.6416 mL | 3.2079 mL | 6.4158 mL |
10 mM | 0.3208 mL | 1.604 mL | 3.2079 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet